201 related articles for article (PubMed ID: 22139390)
1. A phase I study of amrubicin and fixed dose of irinotecan (CPT-11) in relapsed small cell lung cancer: Japan multinational trial organization LC0303.
Kawahara M; Kubo A; Komuta K; Fujita Y; Sasaki Y; Fukushima M; Daimon T; Furuse K; Mishima M; Mio T
J Thorac Oncol; 2012 Dec; 7(12):1845-1849. PubMed ID: 22139390
[TBL] [Abstract][Full Text] [Related]
2. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.
Kobayashi M; Matsui K; Iwamoto Y; Ebi N; Oizumi S; Takeda K; Sawa T; Shibata K; Saka H; Imamura F; Seki N; Saito H; Goto I; Nakagawa K;
J Thorac Oncol; 2010 Jul; 5(7):1075-80. PubMed ID: 20479694
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402.
Nogami N; Hotta K; Segawa Y; Takigawa N; Hosokawa S; Oze I; Fujii M; Ichihara E; Shibayama T; Tada A; Hamada N; Uno M; Tamaoki A; Kuyama S; Ikeda G; Osawa M; Takata S; Tabata M; Tanimoto M; Kiura K
Acta Oncol; 2012 Jul; 51(6):768-73. PubMed ID: 22283472
[TBL] [Abstract][Full Text] [Related]
5. A phase I/II trial of irinotecan plus amrubicin supported with G-CSF for extended small-cell lung cancer.
Harada T; Hamada A; Shimokawa M; Takayama K; Kudoh S; Maeno K; Saeki S; Miyawaki H; Moriyama A; Nakagawa K; Nakanishi Y
Jpn J Clin Oncol; 2014 Feb; 44(2):127-33. PubMed ID: 24379211
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
Morikawa N; Inoue A; Sugawara S; Maemondo M; Harada T; Harada M; Fujita Y; Katoh T; Yokouchi H; Watanabe H; Usui K; Suzuki T; Sakakibara-Konishi J; Nagai H; Kanbe M; Nukiwa T
Lung Cancer; 2017 Sep; 111():38-42. PubMed ID: 28838395
[TBL] [Abstract][Full Text] [Related]
7. Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer.
Kaira K; Sunaga N; Imai H; Kamide Y; Koga Y; Ono A; Kuwako T; Masuda T; Hisada T; Ishizuka T; Yamada M
Int J Clin Oncol; 2016 Apr; 21(2):240-247. PubMed ID: 26266640
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
Okuma HS; Horinouchi H; Kitahara S; Asao T; Sunami K; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Ohe Y
Clin Lung Cancer; 2017 Mar; 18(2):234-240.e2. PubMed ID: 27867001
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
Fukuda M; Nakamura Y; Kasai T; Nagashima S; Nakatomi K; Doi S; Nakano H; Takatani H; Fukuda M; Kinoshita A; Soda H; Tsukamoto K; Oka M; Kohno S;
J Thorac Oncol; 2009 Jun; 4(6):741-5. PubMed ID: 19404211
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer.
Hirose T; Nakashima M; Shirai T; Kusumoto S; Sugiyama T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
Lung Cancer; 2011 Sep; 73(3):345-50. PubMed ID: 21277039
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
Inoue A; Sugawara S; Maemondo M; Mori Y; Oizumi S; Harada M; Taima K; Morikawa N; Ishida T; Kinoshita I; Watanabe H; Suzuki T; Nakagawa T; Saito R; Nukiwa T
Lung Cancer; 2015 Jul; 89(1):61-5. PubMed ID: 26004087
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer.
Igawa S; Yamamoto N; Ueda S; Ono A; Nakamura Y; Tsuya A; Murakami H; Endo M; Takahashi T
J Thorac Oncol; 2007 Aug; 2(8):741-4. PubMed ID: 17762341
[TBL] [Abstract][Full Text] [Related]
13. A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.
Imai H; Sugiyama T; Tamura T; Minemura H; Kaira K; Kanazawa K; Yokouchi H; Kasai T; Kaburagi T; Minato K;
Cancer Chemother Pharmacol; 2017 Sep; 80(3):615-622. PubMed ID: 28761968
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer.
Asakuma M; Yamamoto M; Wada M; Ryuge S; Katono K; Yokoba M; Fukui T; Takakura A; Otani S; Maki S; Igawa S; Yanaihara T; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Masuda N
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1529-36. PubMed ID: 22415148
[TBL] [Abstract][Full Text] [Related]
15. Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130.
Jalal SI; Hanna N; Zon R; Masters GA; Borghaei H; Koneru K; Badve S; Prasad N; Somaiah N; Wu J; Yu Z; Einhorn L
Am J Clin Oncol; 2017 Aug; 40(4):329-335. PubMed ID: 25503432
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Zubkus JD; Murphy PB; Saez RA; Farley C; Yardley DA; Burris HA; Hainsworth JD
J Thorac Oncol; 2009 Dec; 4(12):1555-60. PubMed ID: 19875975
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer.
Yanaihara T; Yokoba M; Onoda S; Yamamoto M; Ryuge S; Hagiri S; Katagiri M; Wada M; Mitsufuji H; Kubota M; Arai S; Kobayashi H; Yanase N; Abe T; Masuda N
Cancer Chemother Pharmacol; 2007 Mar; 59(4):419-27. PubMed ID: 16832665
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802.
Kawashima Y; Inoue A; Sugawara S; Oizumi S; Maemondo M; Okudera K; Suzuki T; Usui K; Harada M; Morikawa N; Hasegawa Y; Saito R; Ishimoto O; Sakakibara T; Asahina H; Nukiwa T
Respir Investig; 2014 May; 52(3):190-4. PubMed ID: 24853020
[TBL] [Abstract][Full Text] [Related]
19. A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer.
Shibayama T; Hotta K; Takigawa N; Tada A; Ueoka H; Harita S; Kiura K; Tabata M; Segawa Y; Nogami N; Kuyama S; Shinkai T; Tanimoto M
Lung Cancer; 2006 Aug; 53(2):189-95. PubMed ID: 16806573
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M
Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
